enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Novo Nordisk - Wikipedia

   en.wikipedia.org/wiki/Novo_Nordisk

   Novo Nordisk A/S is a Danish ... pharmaceutical products and ... in to increase production supply. [48] As of October 2024, Novo Nordisk was the second ...

3. Novo Nordisk to increase supply of weight-loss drug Wegovy - AOL

   www.aol.com/news/novo-nordisk-increase-supply...

   To try to meet demand, Novo Nordisk said, it has expanded the supply chain by contracting with new manufacturers. It plans to sustain this expansion in 2024 by investing about $6.5 billion in ...

4. Exclusive-Thousands turn to Wegovy copies each month as FDA ...

   www.aol.com/news/exclusive-thousands-turn-wegovy...

   More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each month, an industry group told the U.S. drugs regulator in a letter ...

5. Timeline for supply limits on Novo Nordisk weight-loss drug ...

   www.aol.com/news/timeline-supply-limits-novo...

   The FDA, in its drug shortage list, listed the 0.25 mg, 0.5 mg and 1 mg doses of the drug with limited availability and that the duration of shortage was "to be decided", while the larger doses of ...

6. Novo Nordisk lifts curbs on Wegovy prescriptions in the U.S ...

   www.aol.com/news/novo-nordisk-lifts-curbs-wegovy...

   Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday. "In our guidance for the full ...

7. Novo Nordisk to 'significantly' boost U.S. Wegovy doses ... - AOL

   www.aol.com/news/novo-nordisk-flags-continued...

   Novo Nordisk said on Thursday it will supply "significantly" more doses of Wegovy in the U.S. next year, even as it cautioned shortages of the weight-loss injection would continue in the short to ...

8. Ascendis Pharma and Novo Nordisk Sign Collaboration for ...

   lite.aol.com/tech/story/0022/20241104/9266611.htm

   Under the terms of the agreement, Novo Nordisk also receives exclusive rights to expand any resulting metabolic disease products into other therapeutic areas. The lead program in the collaboration is a once-monthly GLP-1 receptor agonist product candidate that will initially target obesity and type 2 diabetes.

9. Novo Nordisk to continue curbs on U.S. supplies of weight ...

   www.aol.com/news/novo-nordisk-hikes-fy-outlook...

   COPENHAGEN (Reuters) -Novo Nordisk will continue to restrict U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug, it said on Thursday as the company struggles to keep up ...